NVNutchavadee Vorasan

Nutchavadee Vorasan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nutchavadee Vorasan has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Axonal-demyelinating differences in functional change in pediatric Charcot–Marie–Tooth and related neuropathies

    by Chonlada Inmongkol, Nutchavadee Vorasan, Sivaporn Limpaninlachat, Niramon Sereephaowong, Pimchanok Kulsirichawaroj, Oranee Sanmaneechai, Joshua Burns

    Charcot–Marie–Tooth disease and related neuropathies (CMTR) are heterogeneous inherited neuropathies with variable progression, yet data on ped

  • Open Access

    Clinical course and outcomes of patients with anti-interferon-gamma autoantibody-associated adult-onset immunodeficiency: an observational cohort study

    by Nasikarn Angkasekwinai, Ekkarat Wongsawat, Nutchavadee Vorasan

    Anti-interferon-gamma autoantibody (anti-IFN-γ-auto-Abs)-associated adult-onset immunodeficiency (AOID) syndrome presents with variable clinical manifestations, and long-term outcome data and natural history remain limited. This single-center study utilized a disease registry of AOID patients (≥18 years) at Siriraj Hospital, Bangkok, Thailand. Clinical outcomes (survival, death, loss to follow-up) as of November 20, 2024 and disease status (remission, non-remission) at each visit were analyzed. A total of 65 patients were recorded over an eight-year period between 2017 and 2024. The mean age of all patients was 56.4 years, and 66% were female. At initial presentation, 95 opportunistic infections were isolated from 61 patients. M. abscessus (44.2%) was the predominant pathogens, followed by M. avium complex (13.7%), salmonellosis (9.5%) and M. tuberculosis (8.4%). Among 53 patients with at least one year of follow-up, 12 (22.6%) achieved remission and 41 (77.4%) remained in non-remission. Antibody levels exhibited a significant decline over time (p < 0.05) across all patients. However, no significant difference in antibody levels was observed between remission and non-remission group (p > 0.05). Notably, median baseline and latest antibody concentration were significantly lower in the remission group compared to the non-remission group, respectively (baseline level: 3.5, IQR 2.8-3.8 vs. 4.0, IQR 3.5-4.2, p = 0.030; latest level: 2.1, IQR 1.8-2.4 vs. 3.0, IQR 2.1-3.6, p = 0.044). This study noted a slight shift in pathogen distribution, even though rapidly growing mycobacteria remain the most common infection. Most patients experienced non-remission, necessitating prolonged antimicrobial therapy. Our findings indicate a declining trend in antibody levels over time. Given the high rates of non-remission and the associated need for extended treatment, immunomodulatory agents should be considered, especially for non-remission patients, to potentially reduce antibody levels and the risk of infection recurrence.